

Fasting blood glucose, glycemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer



Teemu J. Murtola^{1,2}, Ville JY Vihervuori¹, Jorma Lahtela³, Kirsi Talala⁴, Kimmo Taari⁵, Teuvo LJ Tammela^{1,2}, Anssi Auvinen⁶

¹ University of Tampere, Faculty of Medicine and life Sciences, Tampere, Finland

² Tampere University Hospital, Department of Urology, Tampere, Finland

³ Tampere University Hospital, Department of Internal Medicine, Tampere, Finland

⁴ Finnish Cancer Registry, Helsinki, Finland

⁵ Department of Urology, Helsinki University and Helsinki University Hospital, Helsinki, Finland

⁶ University of Tampere, Faculty of Social Sciences, Tampere, Finland

Correspondence to: Dr. Teemu J Murtola, Tampere University Hospital, Department of Urology, M-building, 3rd floor, room 313, PL 2000, 33521 Tampere, Finland. Phone: +358 3 311 65015. E-mail: teemu.murtola@uta.fi

Word count:

ABSTRACT

Background: Diabetic men have lowered overall risk of prostate cancer (PCa), but the role of hyperglycemia is unclear. In this cohort study we estimated PCa risk among men with diabetic fasting blood glucose level.

Methods: Participants of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) were linked to laboratory database for information on glucose measurements since 1978. The data was available for 17,860 men. Based on the average yearly level men were categorized as normoglycemic, prediabetic or diabetic. Median follow-up was 14.7 years. Multivariable-adjusted Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for prostate cancer overall and separately by Gleason grade and metastatic stage.

Results: In total 1,663 PCa cases were diagnosed. Compared to normoglycemic men, men with diabetic blood glucose level had increased risk of PCa (HR 1.52; 95% CI 1.31-1.75). The risk increase was observed for all tumor grades, and persisted for a decade afterwards. Antidiabetic drug use removed the risk association. Limitations include absence of information on lifestyle factors and limited information on BMI.

Conclusions: Untreated diabetic fasting blood glucose level may be a prostate cancer risk factor.

Keywords: Prostate cancer; hyperglycaemia; glyemic control

INTRODUCTION

The relationship between established type 2 diabetes mellitus (DM) and different types of cancer has been investigated broadly. Studies have shown that people with DM have lower risk of developing prostate cancer (PCa) compared with non-diabetics (1,2). This may be due to altered hormone milieu in diabetic men or lower prostate-specific antigen (PSA) leading to less prostate biopsies due to elevated PSA. However, it is not clear whether this concerns also poorly differentiated PCa, as some studies have suggested that the risk could be elevated (3). Glucose metabolism may have an independent role in prostate cancer development and progression (4,5). There is evidence that hyperglycaemia and poor glycemic control and the related hyperinsulinaemia could be the possible links (6-8). Yet there are very few studies concentrating on connections between PCa and blood glucose levels and glycemic control, and the results from available studies are conflicting. Some have reported increased risk of advanced or aggressive PCa among men with higher glucose levels (9), while other studies have reported a protective association between hyperglycemia and PCa (4,10). Indirect support for the role of hyperglycemia as PCa risk factor comes from studies reporting lowered risk among men using antidiabetic drugs, particularly metformin (11).

In this study we investigated the associations between fasting blood glucose and glycemic control (glycated haemoglobin, HbA1c) and PCa risk overall and by Gleason grade and tumor stage in a cohort of men participating in The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) (12), the largest component of European Randomized Study of Screening for Prostate Cancer (ERSPC) (13). The main goal of FinRSPC and ERSPC studies was to find out if systematic screening can decrease prostate cancer mortality. A significant reduction in PCa mortality was observed in the ERSPC study, though with overdiagnosis of well-differentiated prostate cancer. In the FinRSPC study the reduction in PCa mortality was smaller and not statistically significant (12).

MATERIALS AND METHODS

Study cohort

The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) is the largest component of the multinational European Study of Prostate Cancer Screening (ERSPC) (13). In the FinRSPC, all men aged 55-67 from Tampere and Helsinki residential areas were identified between 1996 and 1999. After exclusion of prevalent prostate cancer cases identified from national Finnish Cancer Registry, a total of 80,144 men were randomly assigned either to be screened with PSA at four-year intervals (the screening arm, 31,866 men) or to control arm with no intervention and followed through national registries (48,278 men). The screening finished in 2008, but the follow-up for cancer cases in this study extended until the end of 2014. The available information on prostate cancers were obtained through study database or through The Finnish Cancer Registry for men in the control arm. The information included date of diagnosis, tumor Gleason score and tumor stage at diagnosis, recorded in this study as non-metastatic (all M0 cases) and metastatic (all M1 cases).

The Finnish Cancer Registry is a nationwide registry collecting information of cancer diagnoses from all Finnish health care units and pathology laboratories through mandatory notifications. The registry covers more than 99% of all cancer cases diagnosed in Finland (14).

To obtain information on BMI the participants of the third screening round during 2004-2008 were mailed surveys asking height and weight along with the screening invitations (15). This information was available for 11,698 men in the FinRSPC cohort.

The study cohort was linked to a nationwide prescription database of the Social Insurance Institution (SII) of Finland. The SII is a governmental agency providing reimbursements for the cost of physician-prescribed drugs to all Finnish citizens. From this database we obtained information on usage of prescribed antidiabetic drugs, antihypertensive drugs, statins, NSAIDs and aspirin during

1995-2009. Information on over-the-counter drug purchases or on drugs administered during hospital inpatient periods was not available.

Information on blood glucose level and glycated haemoglobin

The information on results from each measurement of fasting plasma or blood glucose level and glycated haemoglobin (HbA1c) performed at the Pirkanmaa region were obtained from the Fimlab database and linked to the study cohort by using individual identifier number. The data was available from 1978 for fasting blood glucose level and from 1991 for HbA1c. Information concerning indication of blood glucose measurements was not available, but it is most likely that these measurements are a mix of standard health checks, age-dependent health checks and control measurements of diabetic men.

Fimlab Laboratories is one of the leading laboratory companies in Finland (16). Fimlab provides laboratory services, education and research in Pirkanmaa, Central Finland and Tavastia regions. A major part of laboratory measurements in the Pirkanmaa region are done in Fimlab laboratories. Approximately 25% of the FinRSPC participants lived at Pirkanmaa region at baseline.

The study population of the FinRSPC study was linked to the Fimlab database to identify men with at least one available measurement of blood glucose and/or HbA1c during 1978-2015. The information on fasting glucose levels and/or HbA1c levels were available for 19,263 men, thus forming the cohort of this study (Supplementary figure). The information on fasting glucose levels or HbA1c levels were available for 17,860 and 11,736 men, respectively. Each measured fasting glucose level was divided into three categories: normoglycemic if fasting glucose level was under or equal to 6.0 mmol/l measured from plasma or under or equal to 5.5 mmol/l measured from blood; pre-diabetic if glucose level was between 6.0 and 7.0 mmol/l (plasma) or between 5.6 and 6.1 mmol/l (blood) and diabetic if glucose level was over 7.0 mmol/l (plasma) or over 6.1 mol/l

(blood). The HbA1c levels were also divided into three categories: normoglycemic if HbA1c was under 39 mmol/mol or under 5.7%, prediabetic if HbA1c was between 39 and 47mmol/mol or between 5.7 and 6.4%, and diabetic if HbA1c level was over 47mmol/mol or over 6.4%.

Statistical analysis

We used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for overall risk of prostate cancer by fasting glucose and HbA1c levels. Analyses for Gleason 6 or less, Gleason 7-10, non-metastatic and metastatic tumors were performed separately. These separate analyses were carried out in the same way as the overall analysis, but we only included those PCa cases that met the specific criteria, and calculated hazard ratios between different groups for that cancer type. The follow-up commenced from the FinRSPC randomization (baseline) and ended at the date of death, diagnosis of prostate cancer, emigration or end of the follow-up time (31 December 2014), whichever came first. The time axis was years and month since the baseline. The model was adjusted for age only (age-adjusted analysis) and further for the FinRSPC study arm and the use of antihypertensive drugs, cholesterol-lowering drugs, NSAIDs and aspirin (multivariable-adjusted model).

For each calendar year we calculated the average yearly fasting glucose and HbA1c levels based on all measurements within that year. Fasting glucose level and HbA1c were analyzed as time-dependent variables, updated separately for each year after the baseline. All men who did not have any glucose or HbA1c measurement available in certain year was assigned to separate missing-category for that year.

We further calculated the average blood glucose levels both before and after initiation of antidiabetic drug use, i.e. the first recorded purchase of any antidiabetic drug. Fasting glucose level before and after antidiabetic drug use was analyzed as time-independent variables.

The association between fasting glucose level and prostate cancer risk in subgroups was evaluated by repeating the analyses after stratifying the study population by background variables. Subgroup analyses were stratified by use of drugs that are associated with metabolic syndrome and chronic inflammation. We tested effect modification by adding an interaction term between blood glucose level and the effect modifier into the Cox regression model. The interaction term was considered statistically significant if the p-value was ≤ 0.05 .

The temporal association between fasting glucose level and prostate cancer risk was evaluated by performing separate lag time analysis for measurements done five, ten, fifteen and twenty years earlier.

We used IBM SPSS statistics software (version 23) to perform Cox regression analyses. All p-values are two-sided.

Ethics approval of the study

The study has been approved by the ethics committee of the Pirkanmaa Hospital District, decision number R10167.

RESULTS

Population characteristics

Of the 17,860 men, 8,481 were normoglycemic, 5,812 were at the pre-diabetic range and 3,567 men were at the diabetic range of fasting glucose (Table 1). During the median follow-up of 14.7 years after the baseline, a total of 1,663 prostate cancers were diagnosed in the study cohort, 808 in the normoglycemic group, 454 in the pre-diabetic group and 401 in the diabetic group. Median BMI in the diabetic group was non-significantly higher compared to the normoglycemic group.

The use of cholesterol-lowering drugs, antihypertensive drugs and aspirin was more common in the diabetic group compared to the normoglycemic or pre-diabetic group. However, use of NSAIDs and 5 α -reductase inhibitors was less common in the diabetic group (Table 1).

Median PSA was lower among diabetic men in all three FinRSPC screening rounds compared to normoglycemic men (Table 1).

Fasting blood glucose, HbA1c and prostate cancer risk

Compared to the normoglycemic men, overall PCa risk was elevated in diabetic, but not in pre-diabetic men; multivariable adjusted HR 1.52; 95% CI 1.31-1.75 (Table 2). The risk was similarly elevated regardless of tumor Gleason score. However, the risk elevation was limited to non-metastatic tumors; fasting blood glucose level was not associated with risk of metastatic prostate cancer (Table 2). Association between HbA1c levels and PCa risk was not statistically significant. However, the number of men in these analyses was low.

Effect modification by background variables

The connection between fasting glucose level and PCa risk was affected by several background variables (Figure 1). Diabetic blood glucose level was associated with increased risk in the FinRSPC screening arm but not in the control arm (p for interaction < 0.001). The risk association was also modified by the use of antihypertensive drugs; the association was weaker in users of these drugs (p for interaction 0.018). Further, use of antidiabetic drugs generally and in separate analysis metformin use abolished the risk association (p for interaction < 0.001). No clear effect modification by 5-ARI use was observed, either (p for interaction 0.78).

Similar risk modifications were observed also for Gleason score 8-10 tumors (Figure 2). However, the interactions were not statistically significant in this subgroup.

Role of change in fasting glucose levels after initiation of antidiabetic drug use

Changes in fasting blood glucose levels after the initiation of antidiabetic drug use were not associated with changes in prostate cancer risk (Table 3). Similarly, no change in prostate cancer risk was observed by changes in fasting glucose levels after initiation of metformin use.

Long-term effects of fasting glucose levels

Blood glucose level measured 10 years earlier was borderline significantly associated with elevated PCa risk as in our main analysis; diabetic fasting glucose level was associated with increased risk of non-metastatic tumors and Gleason 6 or less tumor (Table 4). Similar, albeit non-significant risk increase were observed also with 15-year lag time. However, no risk associations were observed for the blood glucose levels measured two decades earlier.

DISCUSSION

In this study we observed an association between fasting blood glucose level and elevated prostate cancer risk. This association was more noticeable in the screening arm, and concerned both poorly and well-differentiated cancers. Previous studies suggest that diabetes mellitus and use of antidiabetic drugs are associated with lowered overall prostate cancer risk, while the risk of high-grade tumors may be elevated (17-20). Our findings do not support the risk lowering association for diabetes as a condition, as diabetic fasting blood glucose levels were associated with increased, not lowered prostate cancer risk. This supports role of hyperglycemia as prostate cancer risk factor. Nevertheless, use of antidiabetic drugs abolished the risk increase observed with diabetic fasting blood glucose level. Therefore our study indirectly supports anticancer effects of antidiabetic drugs, but the mechanism of action is probably unrelated to blood glucose levels.

Some previous studies have reported association between diabetes and lowered PSA compared to non-diabetic men (21-23). Concordantly, median PSA was lower also in our study. This would presumably lead to lower incidence of PCa, as fewer prostate biopsies would be performed due to PSA elevation. In a setting of prostate cancer screening this would mean lower PCa incidence among diabetic men especially in the FinRSPC screening arm. In contrast, we observed a stronger association with increased PCa risk in the FinRSPC screening arm, which suggests that prostate cancer incidence among diabetic men is higher compared to non-diabetic men even if the median PSA is lower. The risk elevation seems to apply to all tumor grades as the risk elevation was observed also for high-grade tumors.

A previous meta-analysis of 14 epidemiological studies found increased risk of several cancer types for elevated HbA1c, excluding prostate cancer (4). Concordantly, we did not observe risk associations with HbA1c, only with fasting blood glucose levels.

Another previous study has examined the association between blood glucose and prostate cancer risk. (24). In this case-cohort study of 500 participants insulin concentrations and glucose concentrations were determined from a single overnight fasting serum sample 5 to 12 years before prostate cancer diagnosis. The study suggests an association between PCa risk and elevated fasting serum insulin, but not with elevated glucose levels. In contrast to our study, the observed blood glucose levels were mainly in the normal range, and no diabetic blood glucose levels were observed. Thus our results are in concordance with this previous study, as we did not observe any risk increase even in men with pre-diabetic blood glucose level, only among men at diabetic glucose level.

The significance of blood glucose as PCa risk factor is supported by our earlier findings in which we found connection between changes in genes associated to glucose metabolism and PCa risk (5). Previously reported lower PCa risk among men with diabetes could be explained by use of antidiabetic medication; for example lower PCa risk has been reported among metformin users (25-28). In this study the use of antidiabetic drugs abolished the observed association between high blood glucose levels and elevated risk of prostate cancer. This supports that the treatment of diabetes could remove the risk increase associated with hyperglycemia. However, the changes in blood glucose level after initiation of antidiabetic drug use during the follow-up was not connected to PCa risk, which suggests that the possible antitumor effects of antidiabetic drugs are mediated through mechanisms other than blood glucose control. However, confirmation will be needed from other studies as confidence intervals were relatively wide in our risk estimates.

The association between blood glucose level and PCa risk is likely to be long-term, because the elevated risk was observable also for the fasting blood glucose level measured a decade earlier. This

suggests that diabetic glucose level could increase the risk of initiation of prostate cancer development. To our knowledge this is the first study to examine long-term associations between fasting blood glucose and prostate cancer risk.

However, we did not observe risk associations by HbA1c level, which reflects long-term glucose balance. HbA1c results were available for fewer participants than were fasting glucose measurements, thus these analyses were limited by lowered statistical power. Nevertheless, this difference between the risk associations between HbA1c and fasting glucose suggests that the interaction between blood glucose, insulin and prostate cancer may be complex.

Strengths of our study include large population-based cohort and information on blood glucose measurements starting from the 1980's. We were also able to evaluate the effect of antidiabetic drug on the risk association through comprehensive national prescription database free of recall bias.

The study also has some limitations. We had no information on lifestyle factors, such as smoking, diet or physical activity, which could possibly affect prostate cancer risk and cause confounding (29-31). The available information on BMI was also limited. Because of these factors, residual confounding is possible. Also, because we had no information on the indication of blood glucose measurements, selection bias is possible affecting the generalizability of our results. However, it does not limit our comparisons by blood glucose level because all men with blood glucose measurements available are prone to the same selection. Our study population is almost entirely Caucasian due to homogeneity of the Finnish population; thus our results may not be generalizable to other ethnicities.

In conclusion, diabetic fasting blood glucose level is associated with elevated PCa risk in a population-based cohort of Finnish men, especially in the setting of systematic PSA-based screening. The risk association is long-term, observed a decade in advance of the diagnosis. Use of antidiabetic drugs removes the risk association, supporting the risk lowering effect of these drugs.

ETHICS APPROVAL

The study has been approved by the ethics committee of the Pirkanmaa Hospital District, decision number R10167. The study was performed in accordance with the declaration of Helsinki.

AVAILABILITY OF DATA AND MATERIAL

Data used in this study are available at request from the authors

CONFLICTS OF INTEREST

TJ Murtola: lecture fees from Astellas, Janssen and MSD, paid consultant for Astellas and Jansen. Ville JY Vihervuori: none. J Lahtela: none. K Talala: none, K Taari: lecture fee from GSK, consultant fee from Abbvie, research funding from Medivation and congress travel support from Astellas and Orion. TLJ Tammela: paid consultant for Astellas, GSK, Pfizer, Orion Pharma and Amgen, A Auvinen: lecture fee from MSD, paid consultant for Epid Research.

FUNDING

Funded by competitive research grant from the Pirkanmaa Hospital District, memorial fund of Seppo Nieminen; grant number 150640

AUTHOR'S CONTRIBUTIONS

TJ Murtola, VJY Vihervuori, J Lahtela and A Auvinen designed the study

TJ Murtola, K Talala, K Taari, TLJ Tammela and A Auvinen obtained the data

VJY Vihervuori and TJ Murtola analyzed the data

All authors participated in interpretation of the results

VJY Vihervuori and TJ Murtola wrote the manuscript

J Lahtela, K Talala, K Taari, TLJ Tammela and A Auvinen reviewed the manuscript

All authors consented on manuscript submission and publication

FIGURE LEGENDS

Figure 1. Association between overall prostate cancer risk and blood glucose level in subgroup analysis. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. Pre-D = pre-diabetic, D = diabetic blood glucose level. * P for interaction = 0.229 for pre-diabetic, $p < 0.001$ for diabetic men. ** P for interaction = 0.435 for pre-diabetic, $p = 0.018$ for diabetic men. *** P for interaction = 0.153 for pre-diabetic, $p < 0.001$ for diabetic men. NSAID = non-steroidal anti-inflammatory drugs, ASA= acetylsalicylic acid.

Figure 2. Association between Gleason 8-10 prostate cancer risk and blood glucose level in subgroup analysis. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. Pre-D = pre-diabetic, D = diabetic blood glucose level. NSAID = non-steroidal anti-inflammatory drugs, ASA= acetylsalicylic acid.

REFERENCES



1. Joost H-G Diabetes and cancer: Epidemiology and potential mechanisms, *Diabetes & Vascular Disease Research* 2014;11:390-394
2. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. *Diabetologia*. 2004;47:1071–1078.
3. Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. *Urol Oncol*. 2012;30:735-743.
4. de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? *British Journal of Cancer* 2014;110:2361-2368.
5. Murtola TJ, Wahlros T, Haring A, Taari K, Stenman UH, Tammela TL, Schleutker J, Auvinen A . Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. *Eur Urol*. 2015;68:1089-97.
6. Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Junger I, Hemelrjick MV. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. *Cancer Medicine* 2016;5:1307-1318
7. Pandeya DR, Mittal A, Sathian B, Bhatta B. Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley. *Asian Pac J Cancer Prev*. 2014;15:1031-1033.
8. Turati F, Galeone C, Gandini S, Augustin LS, Jenkins DJ, Pelucchi C, La Vecchia C. High glycemic index and glycemic load are associated with moderately increased cancer risk. *Mol Nutr Food Res*. 2015;59:1384-1394.
9. Hammarsten, J, Högstedt B.. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. *European Journal of Cancer*; 2005;41: 2887-2895


10. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA. Type 2 diabetes mellitus, glycemic control, and cancer risk. *Eur J Cancer Prev.* 2014; 23:134-140.
11. Zingales V, Distefano A, Raffaele M, Zanghi A, Barbagallo I, Vanella L. Metformin: A Bridge between Diabetes and Prostate Cancer. *Front Oncol.* 2017;7:243.
12. Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A. Prostate cancer mortality in the Finnish randomized screening trial. *J Natl Cancer Inst.* 2013;105:719–725.
13. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A. ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet.* 2014; 384:2027–2035.
14. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. *Acta Oncol.* 1994;33:365–369.
15. Sarre S, Määttänen L, Tammela T LJ, Auvinen A, Murtola TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. *Scand J Urol.* 2016;50:267-273.
16. Fimlab laboratories home page. Available at: http://www.fimlab.fi/sivu.tmp?siivu_id=222, Accessed 21November 2016.
17. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. *Cancer Invest.* 2002;20:157-165.
18. Dankner R, Boffetta P, Keinan-Boker L, Balicer RD, Berlin A, Olmer L, Murad H,

- Silverman B, Hoshen M, Freedman LS. Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11-year historical population follow-up study of more than 1 million men. *Diabetologia*. 2016;59:1683-1691
19. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. *Clin Cancer Res*. 2015;21:756-762.
20. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study. *Am. J. Epidemiol*. 2008;168: 925-931.
21. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, Nakamura N. Serum prostate-specific antigen levels in men with type 2 diabetes. *Diabetes Care* 2008;31:930–931.
22. Zhao S, Xia M, Tang J, Yan Y. Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study. *BJU Int.*, published online 2016 Aug 4
23. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. *Am J Epidemiol* 2006;164:978–983.
24. Albanes D, Weinstein SJ, Wright ME, Männistö S, Limburg PJ, Snyder K, Virtamo J. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. *J Natl Cancer Inst*. 2009;101:1272-1279.
25. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. *Ann Oncol.*, published online 2016 Sep 28
26. Raval AD, Mattes MD, Madhavan S, Pan X, Wei W, Sambamoorthi U. Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer. *J Diabetes Res*. 2016;

2016: 2656814.

27. Tseng, C-H Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. *European Journal of Cancer*, 2014;50: 2831-2837
28. Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. *Scand J Urol*. 2017 in press
29. Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. *Nutrition Journal*. 2015;14:125
30. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB. Prospective study of fruit and vegetable intake and risk of prostate cancer. *J Natl Cancer Inst* 2007;99:1200–1209
31. Discacciati A, Orsini N, Wolk A Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer—a dose–response meta-analysis. *Ann Oncol* 2014;25:584–591





Supplementary Figure. Flow chart for forming of the study population. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer with at least one fasting blood/plasma glucose measurement available during 1978-2014.

Table 1. Population characteristics. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer with at least one fasting blood/plasma glucose measurement available during 1978-2014.

	Average fasting blood glucose level during follow-up		
	Normoglycemic	Pre-diabetic	Diabetic
n of men	8,481	5,812	3,567
FinRSPC study arm			
Screening; n (%)	3,154 (37.2)	2,253 (38.8)	1,398 (39.2)
Control; n (%)	5,327 (62.8)	3,559 (61.2)	2,169 (60.8)
Median (IQR) follow-up	17.0 (15.1-18.0)	16.3(13.8-18.0)	15.3(7.1-17.0)
n of PCa cases	808	454	401
Total follow-up time (person years)	130,811	87,400	43,779
PCa incidence / 1000 person years	6.18	5.19	9.16
Gleason score; n (%)			
6 or less	409 (50.6)	215 (47.4)	203 (50.6)
7-10	384 (47.5)	230 (50.7)	189 (47.1)
Missing	15 (1.9)	9 (2.0)	9 (2.2)
Tumor stage; n (%)			
Localized	759 (93.9)	410 (90.3)	374 (93.3)
Metastatic	48 (5.9)	44 (9.7)	25 (6.2)
Missing	1 (0.1)	0 (0.0)	2 (0.5)
Median (IQR) PSA ¹ in			
1st screening round	1.02 (0.62-1.76)	0.97 (0.61-1.69)	1.01 (0.58-2.06)
<i>P for difference*</i>	Ref	0.21	0.47
2nd screening round	1.30 (0.77-2.28)	1.23 (0.72-2.26)	1.16 (0.66-2.31)
<i>P for difference*</i>	Ref	0.13	0.01
3rd screening round	1.43 (0.81-2.49)	1.39 (0.77-2.41)	1.19 (0.67-2.24))
<i>P for difference*</i>	Ref	0.11	< 0.001
Median (IQR) BMI	26.0 (24.2-28.3)	27.7 (25.3-30.6)	28.6 (26.2-31.6)
Antidiabetic medication use; n(%) ²	207 (2.4)	1,370 (23.6)	2,376 (66.6)
<i>P for difference**</i>	Ref	<0.001	<0.001

Statin use; n(%)	3,291 (38.8)	2,708 (46.6)	1,851 (51.1)
<i>P for difference**</i>	Ref	<0.001	<0.001
Antihypertensive drug use; n (%)	5,481 (64.6)	4,387 (75.5)	2,917 (81.8)
<i>P for difference**</i>	Ref	<0.001	<0.001
NSAID use; n (%)	6,845 (80.7)	4,692 (80.7)	2,749 (77.0)
<i>P for difference**</i>	Ref	0.98	<0.001
ASA use; n (%)	1,536 (18.1)	1,159 (19.9)	715 (20.0)
<i>P for difference**</i>	Ref	0.006	0.013
5 α -reductase inhibitor use; n (%)	1,253 (14.8)	724 (12.5)	384 (10.8)
<i>P for difference**</i>	Ref	<0.001	<0.001

* P for difference compared to the normoglycemic group. Calculated with chi-square test.

** P for difference compared to the normoglycemic group. Calculated with Mann-Whitney U- test.

¹ All PSA values measured are from men in the screening arm of the study

² Categorization based on average blood glucose level, thus also users of antidiabetic drugs may be included in the normoglycemic group if they have good blood glucose control

Table 2. Prostate cancer risk by average fasting blood glucose and HbA1c level. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer.

	n of men/PCa cases	Prostate cancer risk									
		Overall	Gleason 6 or less		Gleason 7-10		Localized PCa		Metastatic		
		HR (95% CI) _{age-adjusted}	HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{age-adjusted}	HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{age-adjusted}	HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{age-adjusted}	HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{age-adjusted}	HR (95% CI) _{multivar.-adjusted*}
Fasting blood glucose level											
Normal	8,481/808	Ref	Ref								
Pre-diabetic	5,812/454	1.07 (0.99-1.23)	1.09 (0.95-1.26)	1.03 (0.84-1.27)	1.08 (0.95-1.26)	1.09 (0.89-1.34)	1.10 (0.90-1.36)	1.10 (0.94-1.27)	1.13 (0.97-1.31)	0.75 (0.43-1.31)	0.74 (0.42-1.30)
Diabetic	3,567/401	1.36 (1.19-1.56)	1.52 (1.31-1.75)	1.26 (1.04-1.53)	1.48 (1.21-1.81)	1.38 (1-13-1.70)	1.46 (1.18-1.81)	1.39 (1.21-1.61)	1.57 (1.35-1.82)	0.99 (0.58-1.69)	0.94 (0.54-1.64)
HbA1c level											
Normal	3,978/431	Ref	Ref								
Pre-diabetic	4,342/338	1.13 (0.88-1.44)	1.15 (0.90-1.47)	1.07 (0.75-1.54)	1.11 (0.77-1.59)	1.17 (0.83-1.64)	1.18 (0.84-1.66)	1.13 (0.87-1.46)	1.16 (0.89-1.50)	1.05 (0.42-2.62)	1.08 (0.43-2.70)
Diabetic	2,880/323	0.95 (0.73-1.23)	1.04 (0.80-1.35)	0.77 (0.53-1.13)	0.89 (0.60-1.31)	1.08 (0.75-1.53)	1.11 (0.77-1.59)	0.87 (0.67-1.15)	0.96 (0.73-1.26)	1.77 (0.73-4.30)	1.83 (0.74-4.52)

* Multivariable-adjusted analyses adjusted with age, the FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs or aspirin.

Table 3. Impact of change in fasting blood glucose level after initiation of antidiabetic drug use. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer.

		Prostate cancer risk				
		Overall	Gleason 6 or less	Gleason 7-10	Localized PCa	Metastatic
n of men/PCa cases		HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{multivar.-adjusted*}	HR (95% CI) _{multivar.-adjusted}	HR (95% CI) _{multivar.-adjusted*}
Change in fasting blood glucose level						
No change	427/43	Ref	Ref	Ref	Ref	Ref
Decrease	873/45	0.82 (0.49-1.36)	0.85 (0.39-1.84)	0.74 (0.37-1.47)	0.67 (0.38-1.20)	2.87 (0.87-9.50)
Increased	933/41	0.83 (0.55-1.26)	1.07 (0.59-1.93)	0.62 (0.34-1.13)	0.85 (0.54-1.29)	0.92 (0.23-3.68)

* Multivariable-adjusted analyses adjusted with age, the FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs or aspirin.

Table 4. Association between the fasting blood glucose level 5, 10, 15 and 20 years earlier and prostate cancer risk. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer.

	Prostate cancer risk				
	Overall	Gleason 6 or less	Gleason 7-10	Localized PCa	Metastatic
	HR (95% CI) multivar.-adjusted'				
Average fasting blood glucose level 5 years earlier					
Normal	Ref	Ref	Ref	Ref	Ref
Pre-diabetic	0.91 (0.70-1.17)	0.71 (0.47-1.07)	1.09 (0.78-1.52)	0.89 (0.68-1.17)	1.08 (0.47-2.50)
Diabetic	1.00 (0.78-1.27)	0.63 (0.42-0.94)	1.37 (1.01-1.88)	0.96 (0.74-1.17)	1.25 (0.56-2.76)
Average fasting blood glucose level 10 years earlier					
Normal	Ref	Ref	Ref	Ref	Ref
Pre-diabetic	1.27 (0.78-1.90)	0.63 (0.26-1.52)	1.70 (0.98-2.92)	1.16 (0.73-1.86)	1.97 (0.44-8.82)
Diabetic	1.34 (0.93-1.93)	1.62 (0.97-2.69)	1.31 (0.67-1.91)	1.41 (0.97-2.04)	0.38 (0.04-3.42)
Average fasting blood glucose level 15 years earlier					
Normal	Ref	Ref	Ref	Ref	Ref
Pre-diabetic	0.81 (0.34-1.92)	0.62 (0.14-2.68)	0.93 (0.32-2.76)	0.79 (0.31-2.05)	1.07 (0.12-9.59)
Diabetic	1.03 (0.58-1.82)	1.52 (0.70-3.27)	0.58 (0.23-1.50)	1.22 (0.68-2.20)	-
Average fasting blood glucose level 20 years earlier					
Normal	Ref	Ref	Ref	Ref	Ref
Pre-diabetic	0.30 (0.04-2.20)	0.65 (0.08-5.07)	-	0.32 (0.04-2.35)	-
Diabetic	0.97 (0.41-2.32)	-	1.78 (0.68-4.67)	0.90 (0.36-2.26)	1.51 (0.15-37.8)

* Multivariable-adjusted analyses adjusted with age, the FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs or aspirin.